| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.53B | 4.53B | 5.00B | 4.89B | 4.58B | 4.29B |
| Gross Profit | 1.72B | 1.66B | 1.76B | 1.73B | 1.62B | 1.48B |
| EBITDA | 927.10M | 927.10M | 819.03M | 855.15M | 889.85M | 1.04B |
| Net Income | 565.49M | 567.77M | 493.20M | 540.71M | 549.50M | 688.37M |
Balance Sheet | ||||||
| Total Assets | 6.25B | 6.25B | 6.39B | 6.43B | 6.39B | 6.51B |
| Cash, Cash Equivalents and Short-Term Investments | 325.00M | 325.00M | 514.33M | 742.53M | 817.98M | 965.59M |
| Total Debt | 826.40M | 826.40M | 789.74M | 807.31M | 826.83M | 881.17M |
| Total Liabilities | 2.78B | 2.78B | 2.89B | 2.86B | 2.83B | 2.88B |
| Stockholders Equity | 3.43B | 3.43B | 3.46B | 3.52B | 3.52B | 3.59B |
Cash Flow | ||||||
| Free Cash Flow | 645.14M | 645.14M | 618.93M | 698.27M | 529.50M | 715.37M |
| Operating Cash Flow | 749.10M | 749.10M | 724.43M | 822.63M | 756.72M | 925.81M |
| Investing Cash Flow | -2.06M | -2.06M | -127.41M | -224.50M | -262.50M | -329.00M |
| Financing Cash Flow | -768.12M | -768.12M | -771.02M | -651.43M | -629.90M | -870.93M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $12.96B | 26.16 | 10.64% | ― | 4.21% | -0.63% | |
72 Outperform | $10.04B | -136.74 | -6.10% | ― | 32.81% | -36.32% | |
69 Neutral | $8.65B | 15.89 | 16.26% | 2.57% | -9.43% | 19.14% | |
69 Neutral | $5.76B | 30.41 | 15.52% | ― | 23.16% | 27.38% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
54 Neutral | ― | ― | 0.43% | ― | 1.32% | -84.56% |
On December 16, 2025, Amdocs Limited released its annual report for the fiscal year ending September 30, 2025. The report, which was issued as part of a Form 6-K filing, provides insights into the company’s financial performance and strategic initiatives over the past year. This release is significant for stakeholders as it offers a comprehensive overview of Amdocs’ operational achievements and future outlook, reinforcing its position in the competitive software and services market.
Amdocs Limited has announced its upcoming annual general meeting of shareholders, scheduled for January 30, 2026, in Jersey City, NJ. Key agenda items include the election of ten directors, an amendment to the Employee Share Purchase Plan to increase share issuance by 2.2 million shares, an increase in the quarterly dividend rate, approval of the fiscal year 2025 financial statements, and the ratification of Ernst & Young LLP as the independent accounting firm for fiscal year 2026. These proposals reflect Amdocs’ ongoing strategic initiatives to enhance shareholder value and ensure robust corporate governance.
On November 11, 2025, Amdocs Limited announced its financial results for the fourth quarter and full fiscal year 2025, reporting a revenue of $4.53 billion, a decrease of 9.4% year-over-year due to the phase-out of certain business activities. Despite this, the company achieved a record managed services revenue and improved profitability, driven by operational efficiencies and a focus on high-margin activities. Amdocs also highlighted strong sales momentum and significant international expansion, securing major contracts with companies like TELUS, Lumen Technologies, and British Telecom. The company is increasing its investment in generative AI to unlock new growth opportunities, with a strategic focus on modernizing IT operations and enhancing customer experiences. Looking forward, Amdocs expects revenue growth in the range of 1.7% to 5.7% for fiscal year 2026.